Deutsche Bank analyst James Shin raised the firm’s price target on Gilead (GILD) to $135 from $120 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $140 from $126 at BofA
- Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology?
- Tesla disbands supercomputer team, Trade Desk Q2 spurs downgrades: Morning Buzz
- Gilead and Arcus Advance Promising Colorectal Cancer Study
- Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers